Table 5 Exploratory analyses summary
From: Raltitrexed–eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer
Univariate | Multivariate | ||||||
|---|---|---|---|---|---|---|---|
Variable | Subgroups | No. of patients | 1 year OS (%) | P | HR | 95% CI | P |
PFS | <6 months | 22 | 0.0 | ||||
⩾6 months | 19 | 21.1 | 0.0035 | 4.27 | 1.56–11.67 | 0.007 | |
Surgery | Yes | 18 | 22.2 | ||||
No | 23 | 0.0 | 0.0049 | 2.26 | 0.48–10.79 | 0.31 | |
CHT lines | 1 | 6 | 11.4 | ||||
>1 | 35 | 0.0 | 0.1278 | 1.49 | 0.38–5.83 | 0.58 | |
Age | ⩽60 | 19 | 15.8 | ||||
>60 | 22 | 4.5 | 0.3362 | 1.27 | 0.50–3.21 | 0.62 | |
Gender | Male | 23 | 17.4 | ||||
Female | 18 | 0.0 | 0.0296 | 0.52 | 0.23–1.19 | 0.13 | |
PS | 90–100 | 25 | 12.0 | ||||
70–80 | 16 | 6.2 | 0.2882 | 1.29 | 0.49–3.38 | 0.61 | |
Radiotherapy | Yes | 14 | 11.1 | ||||
No | 27 | 7.1 | 0.3601 | 0.78 | 0.34–1.80 | 0.56 | |
No. of lesions | 2–5 | 24 | 4.2 | ||||
>5 | 16 | 18.8 | 0.4529 | 0.62 | 0.18–2.12 | 0.45 | |
Site: liver | Yes | 33 | 9.1 | ||||
No | 8 | 12.5 | 0.4891 | 0.96 | 0.32–2.88 | 0.94 | |
Site: lung | Yes | 12 | 16.7 | ||||
No | 29 | 6.9 | 0.4457 | 1.06 | 0.31–3.58 | 0.93 | |
Site: pancreas | Yes | 26 | 0.0 | ||||
No | 15 | 26.7 | 0.0011 | 8.46 | 1.34–53.4 | 0.03 | |
Site: peritoneum | Yes | 5 | 0.0 | ||||
No | 36 | 11.1 | 0.3860 | 0.37 | 0.08–1.76 | 0.22 | |
No. of sites | 1 | 7 | 42.9 | ||||
>1 | 34 | 2.9 | 0.0080 | 0.70 | 0.14–3.42 | 0.66 | |
